CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia

Filiaciones

Barragán E:

Clinical Laboratory and Department of Hematology, University Hospital La Fe, Valencia, Spain

Chillón MC:

Department of Hematology, University Hospital of Salamanca, Salamanca Institute for Biomedical Research (IBSAL), Spain

Castelló-Cros R:

Program of Hematology-Oncology, CIMA, University of Navarra, Pamplona, Spain

Marcotegui N:

Program of Hematology-Oncology, CIMA, University of Navarra, Pamplona, Spain

Prieto MI:

Department of Hematology, University Hospital of Salamanca, Salamanca Institute for Biomedical Research (IBSAL), Spain

Hoyos M:

Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

Pippa R:

Program of Hematology-Oncology, CIMA, University of Navarra, Pamplona, Spain

Etxabe A:

Program of Hematology-Oncology, CIMA, University of Navarra, Pamplona, Spain

Rodríguez G:

Department of Hematology, Gregorio Marañón Institute for Health Research, Madrid, Spain

Buño I:

Department of Hematology, Gregorio Marañón Institute for Health Research, Madrid, Spain

Rifón J:

Department of Hematology, Clinical University of Navarra, Pamplona, Spain

Sierra J:

Department of Hematology, Hospital Santa Creu i Sant Pau, Barcelona, Spain

González M:

Department of Hematology, University Hospital of Salamanca, Salamanca Institute for Biomedical Research (IBSAL), Spain

Calasanz MJ:

Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain

Sanz MA:

Clinical Laboratory and Department of Hematology, University Hospital La Fe, Valencia, Spain

Odero MD:

Program of Hematology-Oncology, CIMA, University of Navarra, Pamplona, Spain Department of Biochemistry and Genetics, University of Navarra, Pamplona, Spain